Angelman syndrome: 2026 so far

Clinic data added detail on seizure burden and reported medication experiences.

In the months covered, a retrospective single-center cohort (101 children) offered a detailed real-world snapshot of epilepsy (seizure disorder) in Angelman syndrome. It reported higher therapy-refractory epilepsy (seizures that stay hard to control despite treatment) in deletion genotypes than in non-deletion genotypes. The same report summarized seizure reductions and side effects reported with several commonly used antiseizure medicines. Because it was retrospective, it could not determine which medicine works best. Separately, caregiver and smaller cohort reports also connected deletion subtype with more seizures reported or earlier epilepsy recognition. The seizure types described looked broadly similar across subtypes. This helps set expectations for how seizure burden and treatment experiences can differ in routine care and by genetic subtype, without showing that any one medication is superior.

Research covered in: July 2026, September 2026

CBD updates came from separate clinical observations and mouse-model experiments.

In the months covered, CBD-related findings came from separate observational clinical reports and separate mouse-model experiments, rather than one single line of evidence. In a hard-to-treat pediatric epilepsy clinic group, add-on CBD was often continued for 12-24 months, and seizure reduction was commonly noted. Outcomes were not separated for Angelman syndrome. In a retrospective real-world report of highly purified CBD in 15q11.2-q13.1 duplication/deletion conditions (including Angelman syndrome), CBD use was linked with fewer seizures. In that review, there were no discontinuations due to side effects. Some participants also had reported changes beyond seizures (sleep, behavior, attention), but these were not described for everyone. In an Angelman mouse model, chronic CBD injections were linked to sleep-pattern changes and fewer later seizures after provoked seizures in the lab. Taken together, the months covered support continued interest in CBD, but the evidence remains non-randomized and, in some reports, not specific to Angelman syndrome.

Research covered in: February 2026, April 2026, June 2026

Sleep burden was described in detail; caregiver support showed early feasibility.

New human data in the months covered described sleep challenges as persistent. Caregiver reports described more night waking and snoring than in neurotypical siblings, plus more parasomnias (unusual sleep behaviors, like sleepwalking) and daytime sleepiness. Across the neurodevelopmental conditions studied, overall sleep questionnaire scores were described as fairly stable over about 12 months. The same sleep work suggested that questionnaires focused on sleep-related breathing agreed better with each other than daytime sleepiness tools, which points to limits in how some symptoms are measured. Separately, a small, non-randomized telehealth acceptance and commitment therapy (ACT) program (a skills-based therapy focused on coping and values) reported lower caregiver depression and parenting stress after 9 weeks, without a comparison group. This adds clearer documentation of common sleep burdens and offers an early, non-comparative signal that structured caregiver support can be delivered remotely and may shift caregiver-reported well-being.

Research covered in: August 2026, September 2026

Outcome tools improved reliability and helped interpret small shifts.

In the months covered, several studies worked on making commonly used measures more consistent and easier to interpret. This included caregiver-reported communication tools and EEG (electroencephalogram, a test that records brain electrical activity) signals. ORCA communication scoring and interpretation advanced in several ways: test-retest reliability over 5-12 days, alternative scoring to better capture very low communication ability, and multiple efforts to estimate what size of ORCA change caregivers consider meaningful (with context-dependent thresholds). EEG work also refined measurement by separating delta-band activity into periodic and aperiodic components linked to different abilities, and by showing elevated delta activity in animal models. This gives future studies (and research discussions) more practical ways to judge whether small score or EEG shifts are likely to reflect meaningful change versus measurement noise.

Research covered in: January 2026, February 2026, May 2026, June 2026, August 2026, September 2026

More UBE3A-raising strategies were shown in lab and animals.

So far in 2026, multiple preclinical studies (lab or animal studies, not people) reported ways to increase or reactivate UBE3A, but without patient outcomes. These included a mouse nickase gene-therapy-like approach (AAV9-delivered NmCas9 nickase targeting Ube3a-ATS) that increased UBE3A in mouse brain for at least six months, and a human-specific antisense oligonucleotide (ASO, a short piece of genetic material designed to change gene activity) that raised UBE3A in patient-derived neurons and reactivated UBE3A in transplanted human neurons in mice. Additional preclinical work tested small-molecule approaches targeting Ube3a-ATS, and model-based pathway targets (including myelination/ESRbeta signaling and JNK inhibition in patient-derived neurons) with mixed or partial effects on model readouts. This means the months covered added more disease-targeted directions in models, but did not add new evidence of clinical benefit in people.

Research covered in: February 2026, May 2026, June 2026, September 2026